Back to Search
JOSEPH FAGIN, MD
MD
Family Medicine Physician
NPI: 1215004130Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
G15899(CA)
Research & Publications (20)
Molecular pathology of thyroid cancer: diagnostic and clinical implications.
PMID 19041825·Best Pract Res Clin Endocrinol Metab·2008
6-review
The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations.
PMID 18528508·Trans Am Clin Climatol Assoc·2007
7-preclinical
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
PMID 19487299·Cancer Res·2009
8-other
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
PMID 19478061·Proc Natl Acad Sci U S A·2009
8-other
Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?
PMID 19626825·Oncology (Williston Park)·2009
8-other
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.
PMID 19231149·Curr Opin Cell Biol·2009
6-review
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
PMID 19318445·J Clin Endocrinol Metab·2009
4-observational
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.
PMID 19416908·Proc Natl Acad Sci U S A·2009
7-preclinical
Refractory thyroid cancer: a paradigm shift in treatment is not far off.
PMID 18541893·J Clin Oncol·2008
8-other
RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.
PMID 18519677·Cancer Res·2008
7-preclinical
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.
PMID 18719091·Endocr Relat Cancer·2008
8-other
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
PMID 18713817·J Clin Endocrinol Metab·2008
8-other
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
PMID 18381570·J Clin Endocrinol Metab·2008
7-preclinical
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
PMID 17638907·Cancer Res·2007
7-preclinical
Cell-specific effects of insulin receptor substrate-1 deficiency on normal and IGF-I-mediated colon growth.
PMID 17823215·Am J Physiol Gastrointest Liver Physiol·2007
7-preclinical
Follicular variant papillary thyroid carcinoma arising within an ovarian teratoma.
PMID 17316122·Thyroid·2007
5-case
Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
PMID 16818623·Cancer Res·2006
7-preclinical
Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications.
PMID 16932278·Nat Clin Pract Endocrinol Metab·2006
7-preclinical
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
PMID 16551863·Clin Cancer Res·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9400 ROSECRANS AVE
BELLFLOWER, CA 90706 - Phone
- (562) 461-3000
Quick Facts
- NPI
- 1215004130
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile